Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: Bionano Genomics, IntelliGenome, Pacific Biosciences, Revvity, Angle

NEW YORK – Bionano Genomics said this week that it will effect a reverse stock split of its issued and outstanding common stock at a ratio of 1-for-60 on Jan. 24. As a result, each 60 shares will be automatically combined and converted into one share, valued at $.0001 per share. The company’s common stock will begin trading on the Nasdaq on a split-adjusted basis at market opening on Jan. 27. Equiniti Trust is acting as Bionano's exchange agent for the reverse stock split. 


IntelliGenome said this week that its sputum-free tuberculosis test has obtained breakthrough device designation from the US Food and Drug Administration. The test combines CRISPR with qPCR to detect cell-free DNA of Mycobacterium tuberculosis in blood serum and plasma and can diagnose both pulmonary and extrapulmonary Mtb infections. The firm said it is now well positioned to accelerate a multicenter clinical study underway in the US, Mexico, and Germany. 


Pacific Biosciences said this week that Canada’s Global Institute for Food Security at the University of Saskatchewan is that country’s first certified service provider for the PacBio Revio long-read sequencing system. 


Revvity said this week that its board of directors has approved a quarterly dividend of $.07 per share of its common stock, payable on May 9 to all shareholders of record on April 18. 


UK liquid biopsy firm Angle said this week that it expects full-year 2024 revenues to total £2.9 million ($3.6 million), up 31 percent from £2.2 million in 2023. Loss for the year is expected to be £14.0 million, down 30 percent from £20.1 million in 2023. As of Dec. 31, the firm had £10.4 million in cash, enough to take it into 2026. The firm said its current contracts with large pharma companies are progressing well and that it hopes to sign additional contracts with current and new pharma firms this year. 


In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared on GenomeWeb.